" class="no-js "lang="en-US"> Medivir Partner Infex Therapeutics Receives FDA Designation
Friday, February 03, 2023

Medivir Partner Infex Therapeutics Receives FDA QIDP Designation

Medivir AB has announced that its partner Infex Therapeutics, a leading anti-infectives specialist, has been granted Qualified Infectious Disease Product (QIDP) designation for MET-X by the U.S. Food and Drug Administration (FDA). MET-X is the Company’s broad spectrum Metallo-beta-lactamase inhibitor (MBLI) based on the MBLI program outlicensed by Medivir in 2017 to the AMR Centre, which changed its name to Infex Therapeutics in 2020.

QIDP designation is a U.S. incentive scheme designed to encourage the development of innovative new drugs to treat serious or life-threatening infections. The designation gives MET-X an accelerated FDA regulatory pathway, including priority review, fast-track designation and an additional five years of market exclusivity upon regulatory approval.

During 2022, Infex has presented additional preclinical data and communicated its intention to initiate regulatory safety studies to enable a Phase I clinical trial application in 2023. The QIDP designation is a significant step forward in the development of MET-X. Under the terms of the licensing agreement, Medivir is entitled to a share of potential future revenues from the MET-X programme.

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more